Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry
MADRID, SPAIN and CAMBRIDGE MA.
• José Carlos Gutiérrez-Ramos, President and CEO of Synlogic joins as Independent Director
• NAJETI family fund steps down
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced by means of a “relevant fact” to the CNMV changes on its corporate governing bodies.